Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature

Historically, secondary amyloidosis has been a feared complication of chronic inflammatory conditions. The fibril protein AA derives from the acute phase reactant serum amyloid A (SAA). Long-term elevation of SAA levels remains a major risk factor for the development of AA amyloidosis in rheumatic diseases, and the prognosis may be unpredictable. Nowadays, with increased availability of effective biological agents, the incidence of AA amyloidosis seems to be declining. Still, genetically predisposed subjects with slowly progressive disease and mild symptoms combined with ongoing systemic inflammation may be at risk. Interleukin-6 (IL-6) is one of the drivers of SAA release and effectiveness of the humanized anti-IL-6 receptor antibody tocilizumab (TCZ) for the treatment of AA amyloidosis has been observed in some rheumatic conditions. Herein, we report two male subjects with longstanding ankylosing spondylitis (AS) complicated by renal amyloidosis who received TCZ with rapid and beneficial effects regarding inflammation and proteinuria. To the best of our knowledge, the use of TCZ in AS patients with this extra-articular manifestation has not previously been described. The paper includes histopathology, clinical follow-up, and longitudinal data of the two cases along with a comprehensive review of relevant literature. Mechanisms behind amyloid-mediated tissue damage and organ dysfunction are discussed. Altogether, our data highlight that blocking IL-6 signaling may represent a promising therapeutic option in patients with renal AA amyloidosis.

[1]  J. Wetterö,et al.  C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205 , 2021, Frontiers in Immunology.

[2]  P. Moog,et al.  Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies , 2020, Frontiers in Immunology.

[3]  M. Picken.  The Pathology of Amyloidosis in Classification: A Review , 2020, Acta Haematologica.

[4]  Z. Ballatore,et al.  Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review , 2020, Oncology and Therapy.

[5]  T. Marbury,et al.  Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics , 2019, Journal of clinical pharmacology.

[6]  Y. Okuda.  AA amyloidosis – Benefits and prospects of IL-6 inhibitors , 2018, Modern rheumatology.

[7]  Y. Ando,et al.  First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan , 2018, Internal medicine.

[8]  G. Hatemi,et al.  Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy , 2017, Medicine.

[9]  P. Hawkins,et al.  Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[10]  H. Ozdogan,et al.  Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever , 2017, Orphanet Journal of Rare Diseases.

[11]  I. Narita,et al.  Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  N. Takahashi,et al.  Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience , 2017, Clinical and Experimental Nephrology.

[13]  J. Sieper.  New treatment targets for axial spondyloarthritis. , 2016, Rheumatology.

[14]  B. Hazenberg,et al.  The Prevalence and Management of Systemic Amyloidosis in Western Countries , 2016, Kidney Diseases.

[15]  Lars Erik Kristensen,et al.  The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study , 2015, Arthritis Research & Therapy.

[16]  F. Berenbaum,et al.  AA amyloidosis treated with tocilizumab: case series and updated literature review , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[17]  A. Levy,et al.  Estimating the Occurrence of Renal Complications Among Persons With Ankylosing Spondylitis , 2014, Arthritis care & research.

[18]  K. Migita,et al.  Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin‐6 during treatment for rheumatoid arthritis , 2014, Clinical and experimental immunology.

[19]  R. Costa,et al.  Clinical characteristics of patients with systemic amyloidosis from 2000–2010☆ , 2013 .

[20]  P. Hawkins,et al.  Systemic Amyloidosis in England: an epidemiological study , 2013, British journal of haematology.

[21]  G. Pamuk,et al.  Secondary amyloidosis in ankylosing spondylitis , 2013, Rheumatology International.

[22]  K. Hemminki,et al.  Incidence and survival in non-hereditary amyloidosis in Sweden , 2012, BMC Public Health.

[23]  I. Narita,et al.  Significant association between renal function and amyloid-positive area in renal biopsy specimens in AL amyloidosis , 2012, BMC Nephrology.

[24]  M. Mihatsch,et al.  Renal amyloidosis revisited: amyloid distribution, dynamics and biochemical type. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  P. Westermark,et al.  Serum amyloid A and protein AA: Molecular mechanisms of a transmissible amyloidosis , 2009, FEBS letters.

[26]  L. Dember.  Amyloidosis-associated kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[27]  A. Fernández-Nebro,et al.  Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. , 2005, The American journal of medicine.

[28]  D. Samuel,et al.  Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  A. Bengtsson,et al.  Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus , 2004 .

[30]  M. Dougados,et al.  The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. , 2004, Arthritis & Rheumatism.

[31]  M. Dougados,et al.  Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. , 2003, Arthritis and rheumatism.

[32]  C. Soto,et al.  Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis , 2000, Nature Network Boston.

[33]  D. Droz,et al.  Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  M. Pepys,et al.  Treatment of amyloidosis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[36]  Ankylosing Spondylitis,et al.  Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. , 1993, Annals of the rheumatic diseases.

[37]  D. Feinfeld,et al.  Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  I. Schmid.  AA , 1988, Catalysis from A to Z.

[39]  J. H. Cooper.  An evaluation of current methods for the diagnostic histochemistry of amyloid , 1969, Journal of clinical pathology.

[40]  R. C. Macridis.  A review , 1963 .

[41]  H. Sutton.  AN EPIDEMIOLOGICAL STUDY , 1937 .

[42]  B. Hazenberg.  Amyloidosis , 1933, The Indian medical gazette.